Physician profile
Marc Bloomenstein
NPI 1568428910
$1,365,152.95
in general payments reported to CMS, 2019-2025
33 companies · $294K in 2025
The $294K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130K · 2020: $97K · 2021: $216K · 2022: $230K · 2023: $216K · 2024: $182K · 2025: $294K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $305K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $199K · Consulting Fee: $93K · Travel and Lodging: $71K · Food and Beverage: $14K · Honoraria: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $304,712.04 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $199,100.00 |
| Consulting Fee | $93,266.72 |
| Travel and Lodging | $70,560.28 |
| Food and Beverage | $13,625.15 |
| Honoraria | $11,125.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $230,861.16 | 2019-2025 | Cequa, Bromsite, Xelpros |
| Bausch & Lomb Americas INC. | $202,460.86 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Allergan, INC. | $185,523.33 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $153,315.89 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $114,557.16 | 2020-2022 | |
| Abbvie INC. | $97,550.65 | 2022-2025 | Vuity, Lumigan, Alphagan P |
| Oyster Point Pharma, INC. | $80,251.42 | 2022-2024 | Tyrvaya |
| Sight Sciences, INC. | $73,091.24 | 2019-2025 | Tearcare System |
| Dompe US, INC. | $48,382.19 | 2019-2025 | Oxervate |
| Alcon Vision LLC | $42,185.51 | 2019-2025 | Tryptyr, Eysuvis, Rocklatan |
| Johnson & Johnson Surgical Vision, INC. | $37,584.74 | 2019-2021 | |
| Thea Pharma INC. | $18,697.81 | 2022-2024 | Iyuzeh |
| Harrow Eye, LLC | $18,075.96 | 2023-2025 | Vevye, Tobradex St, Natacyn |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $17,640.53 | 2019-2021 | |
| Alcon Research LLC | $9,015.00 | 2019-2025 | Tryptyr |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $8,104.76 | 2021-2025 | |
| Reichert, INC. | $7,900.00 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $5,080.87 | 2019-2022 | |
| Topcon Healthcare, INC. | $4,500.00 | 2023-2025 | |
| Eyevance Pharmaceuticals LLC | $3,874.69 | 2019-2021 | |
| Tearlab Corp | $1,438.17 | 2022-2023 | Tearlab Osmolarity System |
| Biotissue Holdings INC. | $1,345.18 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $1,179.00 | 2023 | |
| Shire North American Group INC | $1,083.14 | 2019 | |
| Aerie Pharmaceuticals, INC. | $1,062.00 | 2021 | |
| Astellas Pharma US INC | $135.67 | 2023 | |
| Rxsight INC | $85.74 | 2024-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Mallinckrodt Enterprises LLC | $59.34 | 2019 | |
| Mallinckrodt Hospital Products INC. | $52.31 | 2020 | |
| Akorn Operating Company LLC | $23.74 | 2021 | |
| Staar Surgical Company | $15.19 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $11.40 | 2019 | |
| Quidel Corporation | $8.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Bloomenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.